telogen effluvium tirzepatide Does Cause Hair Loss? Side Effects & Treatment Drug-Induced Telogen Effluvium: Medication-Triggered Hair

Clinical Decision Summary Patients and clinicians weighing Mounjaro versus retatrutide face a choice between an approved, commercially accessible drug with 72-week phase 3 data and an investigational agent with 48-week phase 2 data that shows numerically superior weight loss but substantially higher GI discontinuation rates

Theres growing interest in its role as a treatment option not only for those with diabetes but also for people with obesity, a common comorbidity in hypothyroid patients

The report can include or exclude specific tasks by using the checkboxes in the selection screen

More serious adverse effects include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), and acute kidney injury (particularly with severe dehydration from gastrointestinal symptoms)

It is likely that the balance between glutamate and GABA may determine the excitatory/inhibitory balance in the central nervous system and hence the ratio of signal to noise